Hangzhou Just Biotherapeutics Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Merger of Eq.

  • Investors
  • 1

Hangzhou Just Biotherapeutics General Information

Description

Developer of a technology designed to offer global antibody and recombinant protein bio-therapeutics. The company's technology uses protein, process and manufacturing sciences to clear scientific and technical hurdles that block access to protein therapeutics, enabling businesses to develop biologics while accelerating the development process and substantially reducing manufacturing cost.

Contact Information

Website
www.justbiochina.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Science and Technology Park Road, Hangzhou Economic and Technological Development Zone
  • Number 2, Singapore Science and Technology Park Building 5 (Leo Building) 11th floor
  • Hangzhou, Zhejiang
  • China
+86 0571
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Acquirer
Transcenta Holding
Corporate Office
  • Science and Technology Park Road, Hangzhou Economic and Technological Development Zone
  • Number 2, Singapore Science and Technology Park Building 5 (Leo Building) 11th floor
  • Hangzhou, Zhejiang
  • China
+86 0571

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hangzhou Just Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger of Equals 02-Jan-2019 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series B1) 06-Jun-2018 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series B) 08-Aug-2017 $57M $86M Completed Startup
1. Early Stage VC (Series A) 01-Aug-2016 $29M $29M Completed Startup
To view Hangzhou Just Biotherapeutics’s complete valuation and funding history, request access »

Hangzhou Just Biotherapeutics Former Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
ARCH Venture Partners Venture Capital Minority
BOCGI Zheshang Capital Growth/Expansion Minority
Bank of China Investment Bank Minority
Bank of Hangzhou Corporation Minority
Gates Foundation Not-For-Profit Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial

Hangzhou Just Biotherapeutics FAQs

  • Where is Hangzhou Just Biotherapeutics headquartered?

    Hangzhou Just Biotherapeutics is headquartered in Hangzhou, China.

  • What industry is Hangzhou Just Biotherapeutics in?

    Hangzhou Just Biotherapeutics’s primary industry is Drug Discovery.

  • Is Hangzhou Just Biotherapeutics a private or public company?

    Hangzhou Just Biotherapeutics is a Private company.

  • What is Hangzhou Just Biotherapeutics’s current revenue?

    The current revenue for Hangzhou Just Biotherapeutics is .

  • How much funding has Hangzhou Just Biotherapeutics raised over time?

    Hangzhou Just Biotherapeutics has raised $121M.

  • Who are Hangzhou Just Biotherapeutics’s investors?

    ARCH Venture Partners, BOCGI Zheshang Capital, Bank of China, Bank of Hangzhou, and Gates Foundation are 5 of 10 investors who have invested in Hangzhou Just Biotherapeutics.

  • When was Hangzhou Just Biotherapeutics acquired?

    Hangzhou Just Biotherapeutics was acquired on 02-Jan-2019.

  • Who acquired Hangzhou Just Biotherapeutics?

    Hangzhou Just Biotherapeutics was acquired by Transcenta Holding.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »